Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it issued restricted stock units covering a total of 55,114 shares of common stock to 54 new non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The Company is making this announcement as required by NASDAQ rules.
About Exact Sciences
Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at www.exactsciences.com.
Contacts:
J.P. Fielder, 202-746-6352
jfielder@exactsciences.com